Artal Group’s Arcus Biosciences RCUS Stock Holding History

Artal Group’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-270,000	Closed	-$2.15M	–	116
2019 Q2	$2.15M	Sell	270,000 -30,000	-10%	-$300K	0.09%	93
2019 Q1	$3.75M	Hold	300,000	–	–	0.15%	85
2018 Q4	$3.23M	Hold	300,000	–	–	0.12%	81
2018 Q3	$4.18M	Hold	300,000	–	–	0.11%	80
2018 Q2	$3.67M	Hold	300,000	–	–	0.08%	79
2018 Q1	$4.63M	Buy	+300,000	New	+$5M	0.06%	73

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group's RCUS Position: Q3 2019 in Review

Artal Group sold out of Arcus Biosciences (RCUS) in Q3 2019, closing a stake of 270,000 shares — an estimated $2.15M sold.

Artal Group first reported a position in RCUS in Q1 2018 and held it in 6 quarters. The position peaked at $4.63M in Q1 2018. 75 funds tracked by Wall St. Rank hold RCUS as of Q3 2019.

Artal Group reported no remaining Arcus Biosciences position as of Q3 2019 after selling out during the quarter.
Artal Group sold 270,000 Arcus Biosciences shares in Q3 2019, an estimated $2.15M.
Artal Group first reported a position in Arcus Biosciences in Q1 2018 and held it in 6 quarters.
Artal Group's Arcus Biosciences position peaked at $4.63M in Q1 2018.
75 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2019.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.